DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06948435

Active not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

99

Recruiting sites

—

Enrollment

487

estimated

Study population

Hypertension, Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Systolic BP, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06948435
Org study ID27359
Secondary IDJ2A-MC-GZL1Eli Lilly and Company

Timeline

Milestones

Study first posted2025-04-29actual
Study start2025-04-30actual
Last update posted2026-05-29actual
Primary completion2027-09estimated (month precision)
Study completion2027-09estimated (month precision)

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

HypertensionObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•refer to the GZPL master protocol for screening eligibility.

Exclusion criteria

•refer to the GZPL master protocol for screening eligibility.

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
6
Weight & body composition
1
Safety / tolerability / PK
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline to Week 36

Body weight, % change

percent change from baseline, improvement

Cardiometabolic biomarkers

6 endpoints
Primary/protocol endpoint

Change from Baseline in office Systolic Blood Pressure (SBP)

Time frame:Baseline to Week 36

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change from Baseline in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP

Time frame:Baseline to Week 36

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Percent Change from Baseline in Triglycerides

Time frame:Baseline to Week 36

Triglycerides, change

percent change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Percent Change from Baseline in non-HDL Cholesterol

Time frame:Baseline to Week 36

Non-HDL cholesterol, change

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in hsCRP Concentration (mg/L)

Time frame:Baseline to Week 48

hs-CRP, change

percent change from baseline, improvement

LOINC 30522-7

Secondary/protocol endpoint

Change in office SBP in Randomized Withdrawal Population

Time frame:Week 48 to Week 60

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Pharmacokinetics (PK): Steady-State Area Under the Concentration Curve (AUC) of Orforglipron

Time frame:Baseline to Week 36

AUC₀–∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.